Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATNC05 in Atypical Facial Pain
NCT01920087Phase 3Withdrawn
- Sponsor
- Allodynic Therapeutics
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone, clonidine in atypical facial pain (AFP), sponsored by Allodynic Therapeutics. Planned start Mar 2014; status: withdrawn.
02
Drugs
naltrexoneclonidine
03
Conditions
atypical facial pain (AFP)
Beyond the preview
Go deeper on NCT01920087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920087.